OCT-1 function varies with cell lineage but is not influenced by BCR-ABL

Area of Science:

• Pharmacogenomics
• Hematology
• Molecular Biology

Background:

• Imatinib therapy is effective for chronic myeloid leukemia (CML), but resistance occurs in ~25% of patients.
• Octal transporter 1 (OCT-1) activity in mononuclear cells correlates with imatinib response and survival.
• Variability in OCT-1 activity necessitates understanding influencing factors like cell lineage and BCR-ABL.

Purpose of the Study:

• To investigate the influence of cell lineage on OCT-1 activity in CML patients.
• To determine if BCR-ABL expression directly impacts OCT-1 function or expression.
• To elucidate the mechanisms behind OCT-1 variability in CML treatment.

Main Methods:

• Assessed OCT-1 activity and mRNA in neutrophils, monocytes, and lymphocytes from CML patients and normal donors.
• Utilized a cell line model with ectopic BCR-ABL expression to study its role.
• Correlated OCT-1 activity across different cell types and patient statuses.

Main Results:

• OCT-1 activity and mRNA expression were highest in neutrophils and lowest in lymphocytes across all groups.
• Neutrophil OCT-1 activity did not differ significantly between CML patients and normal donors.
• BCR-ABL expression did not directly alter OCT-1, but promoted granulocyte differentiation, increasing OCT-1 activity.

Conclusions:

• Predictive OCT-1 activity in patient mononuclear cells is strongly linked to cell lineage, especially neutrophil presence.
• BCR-ABL likely influences OCT-1 activity indirectly through enhanced granulocyte differentiation.
• Findings suggest cell lineage, not BCR-ABL directly, is key to OCT-1 activity variations affecting imatinib response.